QuidelOrtho (NASDAQ:QDEL) Updates FY 2025 Earnings Guidance

Key Points

• QuidelOrtho updated its FY 2025 earnings guidance, projecting earnings per share (EPS) between 2.070-2.570 while revenue guidance is set at $2.6 billion-$2.8 billion.
• The company's shares opened at $25.95, experiencing a 4.2% decline on the day of the guidance announcement.
• Despite a recent earnings report showing a negative net margin of 16.10%, QuidelOrtho surpassed expectations with an EPS of $0.12 against a consensus estimate of $0.01.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.070-2.570 for the period, compared to the consensus estimate of 2.405. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.7 billion.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Jefferies Financial Group raised shares of QuidelOrtho from a "hold" rating to a "buy" rating and set a $44.00 price target on the stock in a research report on Thursday, May 8th. Citigroup reduced their price target on shares of QuidelOrtho from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Wall Street Zen cut shares of QuidelOrtho from a "buy" rating to a "hold" rating in a research report on Saturday, July 26th. Finally, UBS Group reduced their price target on shares of QuidelOrtho from $29.00 to $26.00 and set a "neutral" rating on the stock in a research report on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, QuidelOrtho has an average rating of "Hold" and a consensus price target of $42.17.

QuidelOrtho Stock Down 2.2%

QDEL stock traded down $0.5770 during midday trading on Wednesday, hitting $26.1730. The company's stock had a trading volume of 167,090 shares, compared to its average volume of 1,313,760. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.12 and a quick ratio of 0.62. QuidelOrtho has a twelve month low of $22.05 and a twelve month high of $49.45. The company's fifty day moving average price is $27.31 and its 200 day moving average price is $31.51. The stock has a market capitalization of $1.78 billion, a P/E ratio of -4.00 and a beta of -0.04.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.11. The firm had revenue of $613.90 million for the quarter, compared to analyst estimates of $612.36 million. QuidelOrtho had a negative net margin of 16.10% and a positive return on equity of 5.29%. The company's revenue was down 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.07) EPS. As a group, equities research analysts predict that QuidelOrtho will post 2.3 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of QDEL. Royal Bank of Canada increased its stake in shares of QuidelOrtho by 1,218.7% during the 1st quarter. Royal Bank of Canada now owns 80,193 shares of the company's stock worth $2,803,000 after purchasing an additional 74,112 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in QuidelOrtho by 10.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company's stock worth $7,987,000 after buying an additional 21,968 shares during the period. Focus Partners Wealth lifted its holdings in shares of QuidelOrtho by 210.9% during the first quarter. Focus Partners Wealth now owns 20,454 shares of the company's stock worth $715,000 after buying an additional 13,876 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of QuidelOrtho in the second quarter valued at about $1,313,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of QuidelOrtho by 250.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company's stock valued at $93,000 after acquiring an additional 2,309 shares in the last quarter. 99.00% of the stock is currently owned by institutional investors and hedge funds.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.